Actuated Medical Inc.

Actuated Medical, Inc. is pleased to announce that Roger B. Bagwell, Ph.D. is now the Actuated Medical Director, Neural Device Operations. This transition reflects the company's continued expansion in the neural device sector and Dr.

Actuated Medical is excited to announce the appointment of Dr. Abdulsamad to their Medical Advisory Board. A highly respected expert in gastroenterology and advanced therapeutic endoscopy, Dr.

Actuated Medical is proud to announce the appointment of Dr. David L. Diehl to its Medical Advisory Board. A board-certified and fellowship-trained gastroenterologist, Dr.

Maureen L. Mulvihill, Ph.D., President & CEO of Actuated Medical, has been named Chair of the Industrial Advisory Board for the Penn State Center for Biodevices. A founding member of the board since its inception in August 2020, Dr.

Actuated Medical is proud to announce the appointment of Dr. I. Emre Gorgun, M.D., MBA, FACS, FASCRS, to its Medical Advisory Board. Dr.

Actuated Medical, a leading innovator in medical device technologies, proudly announces the receipt of a second FDA 510(k) clearance for its GripTract-GI™ Endoscopic Tissue Manipulator (GripTract) product line.

Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options.

Actuated Medical is proud to announce the appointment of Suzy Engwall to its Board of Directors. She is a healthcare innovation leader, speaker, startup advisor, and mentor who has been working to make a change in healthcare for almost 2 decades.

Currently, 62 million Americans are 65 years old or older. Aging in place is always desired but often older adults experience transitions in care to facilities such as hospitals (short-term) or assisted living (long-term).

Actuated Medical, Inc. is pleased to announce that it has been selected as a Contract Research Organization (CRO) under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative with a potential contract value of $35M over 5 years.